Endocyte Inc (ECYT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Endocyte Inc (ECYT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH137442D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Endocyte Inc (Endocyte) is a biopharmaceutical company that develops targeted therapies for the treatment of cancer and inflammatory diseases. The company's pipeline products include Lu-PSMA-617 and Ac-PSMA-617 for radiologand therapy, and FITC CAR-T. Endocyte's proprietary small molecule drug conjugate (SMDC) technology is used to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company develops therapeutic immunotherapy approach that involves potent immune cells, called chimeric antigen receptor T-cell (CAR T-cell) to fight cancer. It has operations in Indianapolis and West Lafayette. Endocyte is headquartered in West Lafayette, Indiana, the US.

Endocyte Inc (ECYT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Endocyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Endocyte Inc, Medical Devices Deals, 2012 to YTD 2018 10

Endocyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Endocyte Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Kyzeo Imaging Enters into Agreement with Endocyte 12

Endocyte Enters into Agreement Seattle Children's Research Institute 13

Licensing Agreements 14

Endocyte Receives Rights from Radiomedix 14

Endocyte Enters into Licensing Agreement with ABX 15

Endocyte Enters into Licensing Agreement with Nihon Medi-Physics for Etarfolatide 16

Equity Offering 17

Endocyte Raises USD201.2 Million in Public Offering of Shares 17

Endocyte Raises USD86.3 Million in Public Offering of Shares 18

Endocyte Plans to Raise up to USD150 Million in Public Offering of Securities 19

Endocyte Raises Funds through Private Placement of Shares and Warrants 20

Endocyte Raises USD4.5 Million in Private Placement of Shares upon Exercise of Warrants 21

Endocyte Completes Public Offering Of Shares For USD 108.7 Million 22

Endocyte Inc-Key Competitors 23

Endocyte Inc-Key Employees 24

Endocyte Inc-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Jul 31, 2018: Endocyte provides second quarter 2018 financial results and operational update 26

May 09, 2018: Endocyte Provides First Quarter 2018 Financial Results and Operational Update 28

Nov 06, 2017: Endocyte Reports Third Quarter Financial Results 30

Aug 08, 2017: Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update 32

May 10, 2017: Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update 34

Mar 10, 2017: Endocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeline Update 36

Corporate Communications 38

Mar 15, 2018: Endocyte Nominates Dawn Svoronos for Election to Its Board of Directors and Announces Other Board Developments 38

Feb 27, 2018: Endocyte Appoints Patrick Machado, J.D. to Its Board of Directors 39

Feb 21, 2017: Endocyte Appoints Michael T. Andriole as Chief Financial Officer 40

Product News 41

10/17/2017: New Potential Treatment for Prostate Cancer Receives Boost 41

09/06/2017: Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release Syndrome Related to CAR T-Cell Therapy 42

04/16/2018: Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting 2018 43

Clinical Trials 44

Sep 05, 2017: Endocyte Announces Presentation at the European Society for Medical Oncology 44

Jun 02, 2017: Endocyte Announces Clinical Update for EC1169 45

May 26, 2017: Endocyte to Announce Updated Data on clinical-stage asset EC1169 at the 2017 American Society of Clinical Oncology Annual Meeting 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

Endocyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Endocyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Endocyte Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Endocyte Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Endocyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Endocyte Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Endocyte Inc, Medical Devices Deals, 2012 to YTD 2018 10

Endocyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Kyzeo Imaging Enters into Agreement with Endocyte 12

Endocyte Enters into Agreement Seattle Children's Research Institute 13

Endocyte Receives Rights from Radiomedix 14

Endocyte Enters into Licensing Agreement with ABX 15

Endocyte Enters into Licensing Agreement with Nihon Medi-Physics for Etarfolatide 16

Endocyte Raises USD201.2 Million in Public Offering of Shares 17

Endocyte Raises USD86.3 Million in Public Offering of Shares 18

Endocyte Plans to Raise up to USD150 Million in Public Offering of Securities 19

Endocyte Raises Funds through Private Placement of Shares and Warrants 20

Endocyte Raises USD4.5 Million in Private Placement of Shares upon Exercise of Warrants 21

Endocyte Completes Public Offering Of Shares For USD 108.7 Million 22

Endocyte Inc, Key Competitors 23

Endocyte Inc, Key Employees 24

Endocyte Inc, Other Locations 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Endocyte Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 18358
Site License
USD 500 INR 36715
Corporate User License
USD 750 INR 55073

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com